🇺🇸 FDA
Pipeline program

Dexlansoprazole

T-GD07-170

Phase 3 small_molecule completed

Quick answer

Dexlansoprazole for Gastroesophageal Reflux is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 2 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Gastroesophageal Reflux
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials